BETABiohacksAI is a research tool for informational purposes only. All outputs are computational hypothesis candidates — not confirmed mechanisms, not medical advice, and not a substitute for professional medical judgment. Independent experimental validation is always required.
BiohacksAI is an evolving scientific literature platform. New compounds and evidence are indexed continuously.
B
○

Epirubicin

An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA.

300+ PubMed studies analyzed · 39 RCTs · Evidence Score: 49.7

Research Domains

Epirubicin has been studied across 15 research domains including 🔬 Oncology, 🫁 Liver & Detox, ⏳ Longevity & Aging, 🔬 Inflammation, ⚡ Energy & Fatigue. The primary research focus is 🔬 Oncology with 76% of studies addressing this area.

Similar Compounds by Shared Targets

The following compounds share molecular targets with Epirubicin, based on binding affinity data from BindingDB and ChEMBL. Sorted by shared target overlap.

Teniposide
8 shared targets
Trabectedin
7 shared targets
Thapsigargin
8 shared targets
Proscillaridin
7 shared targets
Homoharringtonine
5 shared targets
Deslanoside
7 shared targets
Irinotecan
8 shared targets
casin
5 shared targets
Dexrazoxane
4 shared targets
beta
5 shared targets
Loading evidence profile...

This evidence profile for Epirubicin is generated deterministically from 300 PubMed-indexed studies. All data is corpus-verified with Merkle proofs. BiohacksAI does not provide medical advice. Always consult a healthcare professional before starting any supplement regimen.

Data source: PubMed/MEDLINE (NLM). Corpus version: current. Patent pending (EVE-PAT-2026-001). © 2026 Organiq Sweden AB.